Sitagliptin (also named MK-0431 and marketed as Januvia) is a competitive inhibitor of the enzyme dipeptidyl peptidase 4 (DPP-4). Sitagliptin can increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.